Insider Selling: Repligen Co. (RGEN) VP Sells 12,729 Shares of Stock

Repligen Co. (NASDAQ:RGEN) VP Howard Benjamin sold 12,729 shares of the stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $35.34, for a total transaction of $449,842.86. Following the sale, the vice president now owns 36,554 shares of the company’s stock, valued at approximately $1,291,818.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Repligen Co. (NASDAQ:RGEN) traded up $0.27 on Monday, hitting $36.35. 295,253 shares of the stock traded hands, compared to its average volume of 327,281. Repligen Co. has a twelve month low of $28.48 and a twelve month high of $46.81. The firm has a market capitalization of $1,580.00, a P/E ratio of 62.21, a price-to-earnings-growth ratio of 2.35 and a beta of 1.04.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported $0.15 EPS for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.04. The firm had revenue of $36.58 million during the quarter, compared to the consensus estimate of $35.69 million. Repligen had a net margin of 16.93% and a return on equity of 7.57%. The firm’s revenue was up 48.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.08 earnings per share. analysts anticipate that Repligen Co. will post 0.61 earnings per share for the current year.

Several equities research analysts have recently weighed in on RGEN shares. J P Morgan Chase & Co started coverage on shares of Repligen in a research note on Tuesday, December 5th. They set an “overweight” rating and a $42.00 target price for the company. Stephens reiterated an “overweight” rating and set a $50.00 target price on shares of Repligen in a research note on Tuesday, September 26th. Zacks Investment Research downgraded shares of Repligen from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. TheStreet downgraded shares of Repligen from a “b-” rating to a “c” rating in a research note on Monday, November 13th. Finally, CL King started coverage on shares of Repligen in a research note on Monday, November 13th. They set a “buy” rating and a $41.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $44.38.

A number of large investors have recently made changes to their positions in the stock. California Public Employees Retirement System lifted its position in Repligen by 1.6% in the third quarter. California Public Employees Retirement System now owns 122,548 shares of the biotechnology company’s stock valued at $4,696,000 after purchasing an additional 1,948 shares during the period. Janney Montgomery Scott LLC acquired a new stake in Repligen in the third quarter valued at about $539,000. Cubist Systematic Strategies LLC lifted its position in Repligen by 113.7% in the third quarter. Cubist Systematic Strategies LLC now owns 23,288 shares of the biotechnology company’s stock valued at $892,000 after purchasing an additional 12,388 shares during the period. Perceptive Advisors LLC acquired a new stake in Repligen in the third quarter valued at about $3,349,000. Finally, Cornerstone Capital Management Holdings LLC. lifted its position in Repligen by 78.0% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 16,206 shares of the biotechnology company’s stock valued at $620,000 after purchasing an additional 7,100 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/18/insider-selling-repligen-co-rgen-vp-sells-12729-shares-of-stock.html.

About Repligen

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply